Literature DB >> 24006142

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.

John S Yi1, Emily C Decroos, Donald B Sanders, Kent J Weinhold, Jeffrey T Guptill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24006142      PMCID： PMC4230922          DOI： 10.1002/mus.24063

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  9 in total

1.  A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score.

Authors:  Donald B Sanders; Bernadette Tucker-Lipscomb; Janice M Massey
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

2.  Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases.

Authors:  T Y-T Lu; T Jónsdóttir; T Jonsdottir; R F van Vollenhoven; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2008-10       Impact factor: 19.103

3.  The MG Composite: A valid and reliable outcome measure for myasthenia gravis.

Authors:  Ted M Burns; Mark Conaway; Donald B Sanders
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

4.  Long-lasting treatment effect of rituximab in MuSK myasthenia.

Authors:  J Díaz-Manera; E Martínez-Hernández; L Querol; R Klooster; R Rojas-García; X Suárez-Calvet; J L Muñoz-Blanco; C Mazia; K R Straasheijm; E Gallardo; C Juárez; J J Verschuuren; I Illa
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

5.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.

Authors:  David B Clifford; Beau Ances; Craig Costello; Shari Rosen-Schmidt; Magnus Andersson; Deborah Parks; Arie Perry; Raju Yerra; Robert Schmidt; Enrique Alvarez; Kenneth L Tyler
Journal:  Arch Neurol       Date:  2011-05-09

Review 6.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

7.  Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

Authors:  Petra Roll; Arumugam Palanichamy; Christian Kneitz; Thomas Dorner; Hans-Peter Tony
Journal:  Arthritis Rheum       Date:  2006-08

8.  Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.

Authors:  Jennifer H Anolik; Jennifer Barnard; Teresa Owen; Bo Zheng; Sunil Kemshetti; R John Looney; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2007-09

9.  Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.

Authors:  Ted M Burns; Mark R Conaway; Gary R Cutter; Donald B Sanders
Journal:  Muscle Nerve       Date:  2008-08       Impact factor: 3.217
  9 in total
  10 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.

Authors:  Raffi Topakian; Fritz Zimprich; Stephan Iglseder; Norbert Embacher; Michael Guger; Karl Stieglbauer; Dieter Langenscheidt; Jakob Rath; Stefan Quasthoff; Philipp Simschitz; Julia Wanschitz; David Windisch; Petra Müller; Dierk Oel; Günther Schustereder; Stefan Einsiedler; Christian Eggers; Wolfgang Löscher
Journal:  J Neurol       Date:  2019-01-16       Impact factor: 4.849

Review 3.  Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Jason A Vander Heiden; Elba Pascual-Goñi; Richard J Nowak; Kevin C O'Connor
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

Review 4.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

5.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

6.  Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Authors:  Jeffrey T Guptill; John S Yi; Donald B Sanders; Amanda C Guidon; Vern C Juel; Janice M Massey; James F Howard; Flavia Scuderi; Emanuela Bartoccioni; Amelia Evoli; Kent J Weinhold
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-02-26

Review 7.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

8.  Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study.

Authors:  Sijia Zhao; Kai Zhang; Kaixi Ren; Jiarui Lu; Chao Ma; Cong Zhao; Zhuyi Li; Jun Guo
Journal:  BMC Neurol       Date:  2021-11-04       Impact factor: 2.474

Review 9.  Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.

Authors:  C Zografou; A G Vakrakou; P Stathopoulos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

Review 10.  Rituximab for the treatment of multiple sclerosis: a review.

Authors:  Clara Grazia Chisari; Eleonora Sgarlata; Sebastiano Arena; Simona Toscano; Maria Luca; Francesco Patti
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 6.682
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.